ImmunityBio Secures Macau Approval for ANKTIVA, Eyeing Chinese Oncology Market

ImmunityBio Inc. (IBRX) has achieved a pivotal regulatory milestone with the approval of its lead immunotherapy, ANKTIVA® (N-803), by the Macau Health Bureau. This authorization targets patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), providing a critical alternative to radical cystectomy. The approval represents ImmunityBio’s first successful regulatory filing outside the United States, signaling the start of a broader international commercialization phase for the IL-15 superagonist.

The clinical profile of ANKTIVA has been a primary driver of its regulatory success. As an IL-15 superagonist, the therapy works by stimulating the proliferation of natural killer (NK) cells and CD8+ T cells without activating regulatory T cells that could suppress the immune response. In the pivotal QUILT-3.032 trial, which supported both the U.S. FDA and Macau approvals, ANKTIVA demonstrated a 62% complete response rate in patients who had failed standard Bacillus Calmette-Guérin (BCG) therapy. This efficacy, combined with a manageable safety profile, positions ANKTIVA as a potential standard of care in the post-BCG setting.

“

FDA and Macau approvals, ANKTIVA demonstrated a 62% complete response rate in patients who had failed standard Bacillus Calmette-Guérin (BCG) therapy.

Strategically, the Macau approval serves as a sophisticated entry point into the Greater Bay Area (GBA) of China. The GBA is a massive economic and healthcare hub comprising nine cities in Guangdong province plus Hong Kong and Macau, with a combined population exceeding 86 million. Under current regional policies, innovative drugs approved in Macau can often be utilized in designated medical institutions across the GBA before receiving full national approval from China’s National Medical Products Administration (NMPA). This "early access" model allows ImmunityBio to generate real-world evidence and establish a clinical footprint in one of the world’s most significant oncology markets.

From a competitive standpoint, ImmunityBio is navigating a landscape that includes established checkpoint inhibitors like Merck’s Keytruda, which is also approved for certain NMIBC indications. However, ANKTIVA’s unique mechanism as a cell-mediator that works in tandem with BCG offers a differentiated value proposition. The company is also aggressively pursuing combination trials, testing ANKTIVA alongside other immunotherapies for non-small cell lung cancer and colorectal cancer. This multi-indication strategy is essential for justifying the company’s valuation and long-term growth prospects.